Rhenman & Partners Asset Management Ab Inmune Bio, Inc. Transaction History

Rhenman & Partners Asset Management Ab

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.61 - $10.9 $847,957 - $1.4 Million	128,284 Added 256.57%	178,284 $1.21 Million
Q3 2023 Nov 09, 2023	SELL	$6.61 - $10.9 $847,957 - $1.4 Million	-128,284 Reduced 71.95%	50,000 $338,000
Q2 2023 Aug 11, 2023	BUY	$6.5 - $10.09 $1.16 Million - $1.8 Million	178,284 New	178,284 $1.62 Million

5.36M

310K

371K

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $26M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.